Press Room

Latest

2017

2016

2015

2014

2013

2012

2011

2010

2009

2008

2007

2006

2005

2004

2003

2002

2001


News - 2012

USCOM more accurate monitor than blood pressure in pregnancy

October 23rd, 2012

Uscom Ltd today announced publication in the British Journal of Anaesthesia of research from the Department of Anaesthesia and Intensive Care, and the Department of Obstetrics and Gynaecology at The Chinese University of Hong Kong in Hong Kong. The study demonstrated that USCOM was a more accurate method for monitoring circulation in term pregnant women than blood pressure, the current method.

The study looked at the effect of the pregnant uterus on the great vessels and circulation as patients lay on their back and then on their side, and found that USCOM detected changes in circulation that had only previously only been demonstrated using intra-arterial catheters, a method not considered for routine use due to its invasiveness. Blood pressure has therefore become the method for monitoring circulation in pregnancy. However in this study USCOM, a non-invasive method, was demonstrated to be as accurate as the invasive method and more accurate than the current method of blood pressure monitoring.

Executive Chairman of Uscom, Rob Phillips said, “Accurate monitoring of circulation in pregnancy is critical for the health of the mother and the foetus, and this study demonstrates that USCOM is more accurate than blood pressure for monitoring circulation during pregnancy. This research supports a wider role for USCOM in obstetric care.”

References: Lee SWY, Khaw KS, Ngan Kee WD, Leung TY, CritchleyLAH. Haemodynamic effects from aortocaval compression at different angles of lateral tilt in non-labouring term pregnant women. Brit J Anaes. October 2012; doi:10.1093/bja/aes349.
bja.oxfordjournals.org/content/early/2012/10/10/bja.aes349.abstract

Successful quarter for USCOM operations

October 17th, 2012

Uscom Ltd today released commentary to accompany the September quarter Appendix 4C. The 4C confirmed that USCOM met budget and decreased costs for the quarter and its cash position was complimented by the recent successful capital raising.

The Appendix 4C reported a quarterly loss of $344k against a budgeted loss of $341k with a net operating cash outflow of $307k. This result was achieved by steady sales and decreased costs. The cash on hand at the end of the quarter was $1,166,114 compared to $544,463 at the end of the previous quarter.

Executive Chairman of Uscom, Rob Phillips said, “These results reflect steady sales and sound cash control and comes on the heels of our recent successful capital raising. During this period we have been focused on stabilizing the business, capital raising and developing a strategic path forward. While not stellar, these results confirm that we can achieve our plans for the Company even in the current global environment. We have had a number of significant academic developments in this quarter which should support our global marketing activities and feed into sales in the coming quarters. We are looking forward to the remainder of this financial year as we execute our broader commercial strategy.”

New USCOM research presented at world hypertension congress

October 2nd, 2012

Uscom Ltd today announced the publication of three separate presentations at the International Society of Hypertension 24th Annual Scientific Meeting in Sydney on USCOM’s role in improving management of hypertension. The studies were headed by researchers at the University of Queensland Department of Medicine and involved collaboration with The Shandong Provincial Hospital, Shandong, The Great Ormond Street Hospital for Sick Children, London, The Chinese University of Hong Kong, Hong Kong, The Charles Sturt University, Bathurst, The Royal London Hospital, London, and The Guandong General Hospital Guandong.

The research reviewed current hypertension management guidelines, identified potential areas for improvement and proposed new approaches to the management of hypertension based on guidance of therapy according to USCOM determined hemodynamic values as well as blood pressure.

Professor Malcolm West, an author of the papers, said “We have always managed hypertension to blood pressure goals. The guidance of anti-hypertensive therapies to USCOM determined hemodynamic goals as well as blood pressure has the potential for improvements to the cost-effectiveness of hypertension management.” Professor West is a practising cardiologist at The Prince Charles Hospital and the Mayne Professor of Medicine and Head of the Discipline of Medicine at The University of Queensland. He is also Head of the Cardiovascular Research Unit at Prince Charles Hospital with a life long research focus on hypertension.

Executive Chairman of Uscom, Rob Phillips said, “Hypertension has always been an important target application for USCOM. These publications suggest that managing hypertension to USCOM goals as well as blood pressure will lead to more cost-effective care. We are now committed to introducing our technology into the field of hypertension and partnering with an established market leader who has effective global distribution channels. I believe hypertension is really an application in which we can make a significant contribution.”

Hypertension occurs in more than 25% of all adults and is associated with serious cardiovascular complications including heart attack and stroke. In the US alone in 2009 the total cost to treat hypertension was $73.4b, yet worldwide only 5-45% of hypertensive patients achieve blood pressure goals. Awareness, management and control of hypertension has plateaued since 2007 and remains poor.

References:
Lloyd-Jones D, Adams R, Carnethon M, et al. Heart disease and stroke statistics – 2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2009;119:e21-181 http://www.ncbi.nlm.nih.gov/pubmed/19075105
Guo F, He D, Zhang W, Grace Walton R. Trends in Prevalence, Awareness, Management, and Control of Hypertension Among United States Adults, 1999 to 2010. J Am Coll Cardiol 2012;60:599-606 http://content.onlinejacc.org/article.aspx?articleid=1214578

Role for USCOM in cancer treatment

September 25th, 2012

Uscom Ltd today announced the publication of independent research confirming the effectiveness of USCOM cardiac monitoring during cancer treatment. The research was performed collaboratively by researchers from the Medical Department and the Institute of Clinical Chemistry, at the Ludwig-Maximilians University of Munich, Germany and was published in the Cancer Journal Onkologie.

Dr Geiger and her colleagues studied 50 patients being treated for various kinds of cancers with drugs which may be complicated by cardiac damage. They compared results using the current more expensive and time consuming method with those from USCOM and found “Combining…. USCOM and serum biomarkers is feasible for monitoring the immediate and chronic hemodynamic changes during an anthracycline based regimen.” They concluded that “The role of USCOM is evolving in intensive care medicine. In our opinion this technique deserves closer attention in the cardiac monitoring of cancer patient populations.” The research recommended further study of USCOM in the fields of hematology and oncology.

A number of drugs can be used to reduce the growth of the cancers. However these same drugs can damage the heart, so early detection of changes in heart function allows changes in treatment to limit these cardiac complications. This study demonstrated USCOM was cost-effective for detecting these changes and useful for monitoring these patients.

Executive Chairman of Uscom, Rob Phillips said, “Improving treatment of cancer is a massive community responsibility. Accurate monitoring of the heart function of cancer patients during cancer treatment is critical, and this study confirms that USCOM provides a simple cost-effective solution which may lead to improved outcomes. This is further evidence of the platform nature of the USCOM technology and confirms the potentially community wide usefulness of USCOM monitoring.”

Reference:
Geiger S, Stemmler HJ, Suhl P, Stieber P, Lange V, Baur D, Hausmann A, Tischer j, Horster S. Anthracycline-Induced Cardiotoxicity: Cardiac Monitoring by Continuous Wave-Doppler Ultrasound Cardiac Output Monitoring and Correlation to Echocardiography.
Onkologie 2012;35:241-246 (DOI:10.1159/000338335
http://content.karger.com/ProdukteDB/produkte.asp?Doi=338335

Sophisticated investors oversubscribe to Uscom placement

September 5th, 2012

Uscom Ltd today announced the issue of 5.8 million shares at $0.12 in a private placement to sophisticated investors raising $0.696 million. An additional 2,134,997 shares were also subscribed at $0.12 conditional on shareholder approval, raising an additional $256,200.

There are currently 59,924,488 fully paid ordinary shares on issue, including the 5.8 million issued in this placement. This will rise to 62,059,485 shares once approval is given by shareholders to issue the additional shares. The approval is planned to be sought at the Uscom AGM on the 6th of November. The current share price is $0.17 making the capitalized value of the company approximately $10.5 million. The placement was supported by a mix of current shareholders and new investors and the $0.12 subscription price was a 30% discount to the current market price.

Executive Chairman of Uscom, Rob Phillips said, “Capital is always incredibly important, and I am grateful for the on going support of investors and the confidence shown in our new commercial strategy. Our platform technology is an important medical development and has unequalled, world leading, scientific support, and these funds will be used to develop the multi-sector partnerships to deliver the USCOM technology to multiple markets. I believe the company remains significantly undervalued, and this strategy is planned to realise value for shareholders as our market valuation is restored to more reasonable levels.

Uscom opens private placement fully subscribed

August 20th, 2012

Uscom Ltd today announced that it will issue 5.8 million shares at 12 cents as part of a private placement to sophisticated investors. Subscriptions have been received for all 5.8 million of the current placement, however additional applications will be received and any additional shares issued subject to shareholder approval at the AGM on November 6th 2012.

The 5.8 million shares represent the balance of the Company’s 15% capacity under listing rule 7.1. The Board expects to issue the shares on Friday 24th of August.

Uscom Ltd currently has 54,124,488 fully paid ordinary shares on issue prior to this private placement.

USCOM used to reduce mortality in septic shock by 90%

August 2nd, 2012

Uscom Ltd today confirms the announcement by the Bathurst Base Hospital, Greater Western Area Health Service of NSW Health, Australia, that a new strategy combining USCOM and advanced clinical protocols to treat septic shock has reduced mortality by 90% and emergency transport costs by 90%.

The data from 479 Bathurst septic shock patients collected over a 6 year period by The Australian and New Zealand Intensive Care Society Centre for Outcomes and Resource Evaluation (ANZICS CORE) were analysed. The ANZICS CORE database is collected from Intensive Care Units in Australian, New Zealand and Hong Kong and used to benchmark standards of care against comparable units and international standards.

Professor Brendan Smith and Senior Lecturer Veronica Madigan from the Charles Sturt University have been working with the critical care team at Bathurst Base Hospital and researchers from the University of Queensland to develop new concepts around the use of USCOM to treat septic shock. The new method, based on early diagnosis and rapid USCOM guided individualised treatment has reduced the mortality of septic shock in Bathurst from approximately 50% to less than 5%. This is a 90% mortality reduction with a saving of more than 50 lives per year. Further there was a 90% reduction in emergency transfers from Bathurst of septic shock patients from 2006 to 2012, with emergency transport costs being approximately $8000 per transfer.

Professor Smith said “This protocol saves lives and money. Its as simple as that, and there is no reason every Hospital in Australia shouldn’t be adopting this approach to treat septic shock.

Executive Chairman of Uscom, Rob Phillips said, “Professor Smith’s results set new standards by proving that septic shock is curable, and USCOM is central to this management. They treat each patient individually and rapidly, and achieving a less than 5% mortality is unprecedented. If his work were duplicated Australia wide 25,000 lives would be saved per year and many millions of dollars.

Sepsis occurs in 1-2% of all hospitalisations and is responsible for up to 25% of all ICU utilisations, effecting over 18million people worldwide annually, and is responsible for the same number of deaths as heart attacks and 9.3% of all US deaths, with a predicted increase in incidence of 1.5% per annum. Global mortality ranges from 30-60% with treatment costs in the order of US$22,100. A less than 5% in mortality and improvements in the effectiveness of treatment worldwide would have significant health economic consequences.

Percentage mortality and renal failure in patients with diagnosed septic shock

Figure 1: Percentage mortality and renal failure in patients with diagnosed septic shock from ANZICS CORE Adult Database treated at Bathurst Hospital from 2006 to 2012 in annual quarters demonstrating a mortality reduction from 55% to less than 5%.

References:

USCOM "State of the Art" for hypertension in pregnancy

July 31st, 2012

Uscom Ltd today announced three presentations at the international society for Hypertension in Pregnancy (ISSHP) in Geneva Switzerland. The presentations included a State of the Art lecture and demonstration of the use of USCOM by Professor Valensise of the Department of Obstetrics and Gynaecology at the University of Rome Tor Vergata.

Hypertension is the leading cause of maternal and peri-natal mortality and morbidity globally, and Professor Valensise’s presentation demonstrated how he uses USCOM to improve the management of hypertension in pregnancy in his “state of the art” lecture.

An additional 2 research papers were presented at the ISSHP meeting in Geneva demonstrating the potential contribution USCOM can make to improving maternal and fetal care in this important clinical group. The research was presented by Dr Scala and colleagues from the Department of Obstetrics and Gynaecology of the University of Rome Tor Vergata, and by Dr Goodyear and colleagues from the Department of Fetal Medicine, Institute for Women’s Health, University College London Hospitals, London, UK.

Dr Goodyear’s group concluded from their study “This simple technique (USCOM) is likely to facilitate large scale studies of maternal cardiovascular function in pregnancy.” This research was also presented at the meeting of the International Society for Obstetric Medicine in Oxford, UK in early July 2012.

Executive Chairman of Uscom, Rob Phillips said, “Hypertension in pregnancy is another critical clinical market in which USCOM is now being recognized. These studies confirm that USCOM use will improve the outcomes of mothers and babies, and it’s applications like these for which USCOM was developed. These studies confirm that USCOM is a standard of care platform technology, and suggests the home care hypertension market is a future focus for our Company.”

Healthy pregnancy requires a normal increase in circulation to support the growth of the fetus. The accurate and early identification of circulatory abnormalities allows accurate intervention to improve maternal and fetal outcomes. Due to the non invasive and accurate nature of USCOM, it is ideal for guiding interventions in the sensitive maternal circulation.

References:
Gemma Goodyear, Ehizele Joseph, Asma Khalil “Cardiac output and systemic vascular resistance in normal pregnancy.” International Society for Obstetric Medicine – Oxford, UK. July 7-8

Herbert Valensise. “Preeclampsia is a heart disease.” – State of the Art lecture. International Society for Study of Hypertension in Pregnancy. Geneva, Switzerland July 2012

Goodyear G, Joseph E, Khalil A. “Cardiac output and systemic vascular resistance in normal pregnancy and in control non-pregnant women.” Pregnancy Hypertension: An International Journal of Women’s Cardiovascular Health 2012;2(3):292-293

Scala RL, Tiralongo GM, Pisani I, Gagliardi G, Lo Presti D, Valensise H. “Total vascular resistances in early pregnancy: A key to understand maternal factors inducing spontaneous abortion.” Pregnancy Hypertension: An International Journal of Women’s Cardiovascular Health 2012;2(3),LB007

New substantial shareholding announced to market

July 20th, 2012

Uscom Limited was today notified that Dr Stephen Woodford now holds 2,721,475 shares or 5.03% of the Company’s 54,124,488 issued fully paid ordinary stock.

Dr Stephen Woodford is a Private Anaesthetist and Research Physiologist working through The Brisbane Waters Private Hospital and the Australian School of Advanced Medicine (ASAM) at Macquarie University. Dr Woodford will be presenting results of his cardiovascular research at the American Society of Anesthesiology meeting in Washington in October, 2012. Dr Woodford bought his first USCOM device last year and has continued using the device in clinical practice whilst building his stake in the Company.

Dr Woodford said “I like the Company and I like the technology and I see it as a sound commercial opportunity; this is a great Company which is undervalued. Cardiovascular medicine has the potential for many improvements and Uscom is a company poised to lead these changes.”

Executive Chairman of Uscom, Rob Phillips said, “Dr Woodford is a highly respected clinician and researcher and understands the technology and the benefits it can deliver. He is also a shrewd investor who understands the corporate medical device environment. We welcome him to the Company as a substantial shareholder and look forward to the value his presence on the register will add.”

Uscom will release the initial substantial shareholder notice as soon as it is received from the shareholder.

Research shows USCOM is the best Doppler cardiac monitoring method

June 26th, 2012

Uscom today announced the publication of new clinical evidence which was presented at the World Congress of Anesthesia 2012 and published in the British Journal of Anesthesia, further confirming the gold standard status of the USCOM cardiac output monitor in Aneasthesia.

Uscom Chief Executive Rob Phillips said, “This new study in the BJA confirms that USCOM can replace the CardioQ device in anaesthesia. The CardioQ device has outcomes evidence confirming lifesaving and cost limiting benefits which is being used to support Government adoption guidelines in the UK NHS. The study demonstrates that USCOM can achieve superior results noninvasively and at reduced cost. This study also confirms USCOM’s claim to be the gold standard platform cardiac monitoring technology”.

The publication by Professor Lester Critchley from the Prince of Wales Hospital in Hong Kong, compared USCOM with an alternate method endorsed by the United Kingdom NHS NICE Guidelines, CardioQ Doppler, in high risk surgery patients during anaesthesia. Professor Critchley found that while both methods were acceptable, the CardioQ method was inaccurate at low and high cardiac output values, the values where accuracy becomes critical, while USCOM remained accurate throughout.

The CardioQ Doppler requires insertion of a single patient use intra-oesophageal probe costing between $100 to $200, while USCOM is totally noninvasive, reusable and has no consumables. Anesthesia is an important clinical application and growing market for USCOM.

This study follows the recognition by the UK NHS Intraoperative Fluid Management Technologies Pack published by the United Kingdom NHS Technology Adoption Centre last month citing USCOM as a preferred method of fluid management in high risk surgery.

Reference: Critchley LA. Differences between CardioQ and USCOM Doppler cardiac output readings in high risk surgical patients. British Journal of Anaesthesia 2012; 108(S2): ii113. doi:10.1093/bja/aer479

http://bja.oxfordjournals.org/content/108/suppl_2.toc

German study highlights new critical care market and endorses USCOM

June 5th, 2012

Noninvasive cardiac monitoring company Uscom Ltd today announced the publication of new independent peer reviewed research demonstrating USCOM’s role as a standard of care for accurate and important cardiac monitoring of critical care patients on ventilators.

The USCOM device already has major applications in pediatrics, emergency and intensive care medicine and anesthesia, as well as for management of adult and pediatric sepsis, hypertension, heart failure and for the guidance of cardiovascular fluid and drug therapy. This study identifies the accurate calibration of ventilators as an important clinical application for the patent protected USCOM platform technology, and a new and substantial market.

This new publication is based on a study performed on patients with pneumonia and septic shock admitted to the Intensive Care Unit of Ludwig-Maximilians-University Munich, which found USCOM was, “an accurate, easy to use, non-invasive device that detected irregularities in heart function and helped guide medical treatment.” and concluded that “USCOM constitutes an important tool for easy, rapid and reliable diagnosis and haemodynamic monitoring of critically ill patients.”

Executive Chairman of Uscom, Rob Phillips said, “This study shows that ventilators should be calibrated with USCOM. This is more far reaching, practice changing research which at some time will shift the medical monitoring market. Our sector dominating evidence has great value, and our focus is now to develop partnerships with established marketing, distribution and sales organizations which can efficiently and with scale deliver the USCOM technology into multiple revenue opportunities rapidly as practice responds to our mounting evidence.

Mr Phillips said, “These partnerships will allow us to deliver modular versions of USCOM into portable ultrasound units, monitoring suites, and now into ventilators, as well as continue with stand alone sales into current and new markets. These licensing partnerships are envisaged to deliver strong profitability to shareholders and be the foundation of the Uscom of the future.”

Ventilation of patients with impaired lung function is an increasingly common treatment in critical care medicine and inappropriate ventilator settings can impair cardiac function, making the patient worse. So an accurate measurement of cardiac output is critical for determining the optimal ventilation settings. Currently cardiac monitoring during ventilation is infrequent because the monitoring methods are invasive and/or inaccurate.

USCOM is cleared for use by the US Food & Drug Administration (FDA) and is sold in North America, South America, Europe, the Middle East, Australia, New Zealand, China and South East Asia.

References: Horster S, Stemmler HJ, Sparrer J, Tischer T, Hausman A, Geiger S. Mechanical ventilation with positive end-expiratory pressure in critically ill patients: comparison of CW-Doppler ultrasound cardiac output monitoring (USCOM) and thermodilution (PiCCO). Acta Cardiol 2012; 67(2): 177-185, doi: 10.2143/AC.67.2.2154208

http://www.ncbi.nlm.nih.gov/pubmed/22641975

New Research - USCOM Can Replace Invasive Cardiac Monitors

May 17th, 2012

Noninvasive Cardiac Output Monitoring manufacturer Uscom Ltd (ASX code: UCM) today announced the publication of new peer reviewed research confirming its cardiac monitor, the USCOM 1A, was more accurate than current technologies used to monitor cardiac output.

The results of the study by the prestigious Howard Florey Institute in Melbourne and The University of Queensland in Brisbane is published in the latest Journal of Critical Care Research and Practice.

The current gold standard cardiac monitor is the Pulmonary Artery Catheter (PAC) which involves insertion of a catheter into a patient’s neck or groin and then positioning the catheter in their arteries through the heart, while USCOM simply involves placing a small ultrasound probe on the chest. This study compared the two methods. The researchers surgically implanted accurate measurement devices onto the great cardiac arteries of sheep, and then monitored their cardiac output using USCOM and PAC at rest and as medications were introduced. They found that USCOM had a 1% error compared with the surgical device, while the PAC error was 17%, and that USCOM was 6 to 8 times more accurate than the PAC for detecting changes associated with the common drugs used in cardiovascular management. The study concluded that USCOM was a noninvasive and accurate replacement for PAC.

Professor Malcolm West, the Mayne Professor of Medicine and Head of the Discipline of Medicine at the University of Queensland and an author of the paper said “The USCOM device is a simple method of accurately and noninvasively measuring central circulation, a goal of cardiology for many years. To be noninvasive is a great advantage over the PAC, to be noninvasive and much more accurate means the device has the potential to change the way we approach management of many cardiovascular diseases including sepsis, heart failure and hypertension.”

The paper found that USCOM’s accuracy is unequalled by other clinical methods which explains results found at the Cedars Sinai Intensive Care Department in Los Angeles, published in 2008 in the American Journal of Surgery which found that “USCOM could reliably replace PAC in most clinical situations”. The Swan Ganz PAC has been the standard of human cardiac output measurement since its introduction by Drs Swan and Ganz in the Cedars Sinai Intensive Care Department in 1970. The PAC is associated with a significant risk of death and infection and is confined to critical care use in adults, while alternatively USCOM is totally noninvasive and can be used in a variety of clinical and research applications in adults, children and neonates.

Uscom Chief Executive Rob Phillips said, “This new study adds to the growing global body of independent evidence which demonstrates that our USCOM device offers critical care clinicians a new gold standard for cardiovascular monitoring which can replace costly and dangerous catheter based technologies”.
“It confirms that our growing worldwide customer base has the very best tool available to guide lifesaving cardiovascular treatments and improve the management of critical and widespread diseases such as sepsis, heart failure and hypertension”.

Mr Phillips also said the data confirmed Uscom’s marketing strategy to focus on the needs of hospitals worldwide for more accurate, noninvasive techniques that improve patient care at the same time as reducing the risk of infections and mortality and reducing costs.

Uscom’s non-invasive system is an Australian developed, patent protected technology that uses external ultrasound similar to that used in pregnancy. The ultrasound signal bounces off the red blood cells as they flow across the cardiac valves producing a unique echo from which the device can then count the cells with high accuracy. The USCOM monitor has many applications ranging from paediatrics, critical care, anaesthesia and emergency medicine. New markets are centred on sepsis, heart failure and hypertension, the great global challenges of health care.

References:
Jain S, Vafa A, Margulies DR, Liu W, Wilson MT, Allins AD. Noninvasive Doppler ultrasonography for assessing cardiac function: can it replace the Swan-Ganz catheter? Am J Surgery 2008:196(Dec);961-968.
Thiel SW, Kollef MH, Isakow W. Non-invasive stroke volume measurement and passive leg raising predict volume responsiveness in medical ICU patients: an observational cohort study. Critical Care 2009;39:666-688.
Phillips RA, Hood SG, Jacobson BM, West MJ, Wan L, May CN. Pulmonary artery catheter (PAC) accuracy and efficacy compared with flow probe and transcutaneous Doppler (USCOM): An ovine validation. Crit Care Res Prac 2012;doi:10.1155/2012/621496.
http://www.hindawi.com/journals/ccrp/2012/621496/

New UK NHS Guidelines include USCOM for improving surgical care

May 11th, 2012

Uscom Ltd today announced that USCOM has been included in new Intraoperative Fluid Management Technologies Pack by the United Kingdom NHS Technology Adoption Centre. The management pack describes the “What, Why and How” to improve patient management and care during major and high risk surgery by improved management of fluid. The Guidelines have been published “to help Trusts implement the technology and realise the benefits it can bring.”

These NHS guidelines summarise the benefits of implementation of intra-operative fluid management which include proven life savings and improved patient recovery time and cost savings. Thus the adoption of these recommendations will be driven by benefits to patients and health care providers.

USCOM is a new and specialized device for fluid optimization and has the advantage of being extremely accurate and totally noninvasive and is validated for use in neonates, children and adults. Fluid is the most common critical care intervention in neonates, children and adults being performed on many millions of patients per year. While the current recommendations are directed at intraoperative optimization in adults only, recent evidence suggests improvements in fluid management should also be implemented in neonates, children and adults in all clinical applications.

Executive Chairman of Uscom, Rob Phillips said, “Uscom have conceived and built the practice leading USCOM hemodynamic monitor to meet this critical clinical need. This recognition by the NHS is a response to the overwhelming evidence that improved haemodynamic management saves lives and reduces cost. This evidence will inevitably become a driver of adoption in the new cost sensitive health management age all over the world. Doppler has the highest levels of effectiveness for monitoring haemodynamics. While alternate methods are invasive or require sedation, USCOM is totally noninvasive and accurate and so can be used outside the operating room, and has no consumable costs like its competitors. These Government led guidelines are verification of the message Uscom has been spreading for the last 10 years; improved management of fluid saves lives and money and USCOM is the most accurate and cost effective method. Fluid management is another area in which USCOM is now being recognized as a standard of care.”

References:
http://www.ntac.nhs.uk/
Thiel SW, Kollef MH, Isakow W. Non-invasive stroke volume measurement and passive leg raising predict volume responsiveness in medical ICU patients: an observational cohort study. Critical Care 2009;39:666-688.

Uscom expands distribution

March 19th, 2012

Uscom Limited today announced the appointment of 7 new distribution partners in China. This appointment takes to 14 the number of sub-distributors in China. The appointments and management of these distributors is the responsibility of Pacific Medical Systems Limited, the Asia Pacific distributor for the USCOM and OXYCOM products.

This rapid expansion has been driven by the appointment of Mr Herbert Cheng to the staff of Pacific Medical Systems as Head of Business Development in China. Mr Cheng’s specific task is to review the current Chinese distribution as well as recruit new distributors. Uscom now has representation in 14 of the 23 provinces of China, up 43% from 8 previously, and in all 4 of the 4 municipalities. A further 6 provinces are currently being evaluated for possible distributor signings.

Pacific Medical Systems were responsible for 50% of all worldwide USCOM user sales in 2011, and the current increase in distribution in China is expected to increase USCOM sales over the next 12 months.

Executive Chairman of Uscom, Rob Phillips said, “This expansion of distribution in China is an important part of our global growth strategy. While the rest of the world remains economically parlous, China continues to grow strongly particularly in the field of health, with a commitment in the most recent 5 year economic plan to increase medical device spending by 20% per annum. I have just returned from 3 weeks with Pacific Medical Systems in China and we are aggressively expanding on this wave of increased spending as the quality of Chinese Health care continues to improve with the adoption of sophisticated practice leading technology such as USCOM.”

Mr Jules Flach, Founder and CEO of Pacific Medical Systems said, “We have a close partnership with Uscom Ltd and a strong commitment to the USCOM products. We are working with focus to drive USCOM adoption in the increasingly sophisticated and rapidly growing Chinese medical market.”